Nitrate’s Effect on Activity Tolerance in Heart Failure With Preserved Ejection Fraction Trial
Rosita Zakeri(King's College London), Margaret M. Redfield(Mayo Clinic in Arizona), Julio A. Chirinos(Philadelphia VA Medical Center), Adrian F. Hernandez(Duke University), Gabriel A. Koepp(University of Vermont), Barry A. Borlaug(Mayo Clinic), Peter VanBuren(University of Vermont), Víctor G. Dávila‐Román(Washington University in St. Louis), Kevin J. Anstrom(University of North Carolina at Chapel Hill), Prateeti Khazanie, Martin M. LeWinter(University of Vermont Medical Center), James A. Levine(WinnMed), Lisa de las Fuentes(Washington University in St. Louis)
Cited by 36
Related Papers
Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2017|2.1k
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
|The Lancet|2018|1.8k
Medical Therapy for Heart Failure With Reduced Ejection Fraction
|Journal of the American College of Cardiology|2018|1.3k
Exercise Hemodynamics Enhance Diagnosis of Early Heart Failure With Preserved Ejection Fraction
|Circulation Heart Failure|2010|1.1k
Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment
|European Heart Journal|2010|1.1k